Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177352 · ClinicalTrials.gov registry record · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
A Phase 3 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 13,000
- Enrollment target
- 20
- Study locations
NCT07177352 is a Phase 3 study of Alzheimers Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 13,000 participants, above the 3,970-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (227% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07177352, a Phase 3 study of Alzheimers Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 13,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (20)
Florida
- JEM Research LLC - Atlantis
- K2 Medical Research-Winter Garden - Clermont
- K2 Medical Research - The Villages - Lady Lake
- K2 Medical Research, LLC - Maitland
- Visionary Investigators Network- Neurology Aventura - Miami
- Renstar Medical Research - Ocala
- Charter Research - Winter Park/Orlando - Orlando
- Conquest Research - Lake Nona - Orlando
- Alzheimer's Research and Treatment Center - Stuart
California
- Sun Valley Research Center, Inc. - Imperial
- Inglewood Clinicals - Inglewood
- Irvine Center for Clinical Research - Irvine
- Healthy Brain Clinic - Long Beach
- Oakland Clinical - Oakland
- Riverside Clinical - Riverside
- Syrentis Clinical Research - Santa Ana
- Cenexel California Neuroscience Research, LLC - Sherman Oaks
Arizona
- Banner Alzheimer?s Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,000 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2035-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07177352
The ClinicalTrials.gov registry entry for NCT07177352 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 13,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,970-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (227% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT07177352 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07177352 about?
NCT07177352 is a clinical study titled "Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies". This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
What is the current status of trial NCT07177352?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 13,000 participants. The study started on 2025-07-02. Estimated completion is 2035-07-31.
What conditions does trial NCT07177352 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07177352?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT07177352?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07177352 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.